Mavodelpar sodium clinical trials
Also written REN001.
A product of Mavodelpar; its studies count on that page too.
How each study uses mavodelpar sodium is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2019 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Mavodelpar
Studies
Open first, then newest update. How each study uses mavodelpar sodium is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)TerminatedPhase 2/3Reneo Pharma LtdNCT05267574Written as REN001
- A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation DisordersCompletedPhase 1Reneo Pharma LtdNCT03833128Written as Low Dose REN001
- A Study of the Safety of REN001 in Patients With McArdle DiseaseCompletedPhase 1Reneo Pharma LtdNCT04226274Written as REN001
- A Study of the Safety of REN001 in Patients With Primary Mitochondrial MyopathyTerminatedPhase 1Reneo Pharma LtdNCT03862846Written as REN001
- Safety Study of HPP593 in Subjects During and After Limb ImmobilizationTerminatedPhase 1High Point Pharmaceuticals, LLC.NCT01524406Written as HPP593
Codes
What other systems call mavodelpar sodium · ClinicalTrials.gg INT018498
- UNII (FDA) XRP79L5C2XMAVODELPAR SODIUMOne source FDA
- NCI Thesaurus C203238Mavodelpar SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XRP79L5C2X | MAVODELPAR SODIUM | One source FDA |
| NCI Thesaurus | C203238 | Mavodelpar Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.